SSY Group Ltd. | Income Statement

Fiscal year is January-December. All values HKD Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
2,745
2,091
2,222
2,361
3,076
4,181
Cost of Goods Sold (COGS) incl. D&A
1,563
1,067
1,216
1,209
1,344
1,639
Gross Income
1,182
1,025
1,006
1,152
1,733
2,542
SG&A Expense
739
444
515
576
888
1,476
EBIT
443
617
491
640
845
1,066
Non Operating Income/Expense
100
1
31
1
6
77
Interest Expense
51
45
46
53
57
51
Pretax Income
493
580
480
590
797
1,079
Income Tax
82
89
75
98
134
165
Equity in Affiliates
-
-
2
2
-
-
Consolidated Net Income
412
492
403
490
664
915
Net Income
412
492
403
490
665
912
Net Income After Extraordinaries
412
380
403
490
665
912
Net Income Available to Common
412
542
403
490
665
912
EPS (Basic)
0.14
0.20
0.14
0.17
0.23
0.30
Basic Shares Outstanding
2,930
2,945
2,916
2,830
2,844
2,995
EPS (Diluted)
0.14
0.20
0.14
0.17
0.23
0.30
Diluted Shares Outstanding
2,942
2,961
2,922
2,853
2,913
3,041
EBITDA
588
778
702
881
1,101
1,342
Other Operating Expense
-
36
-
64
-
-
Non-Operating Interest Income
2
8
3
2
3
13
Minority Interest Expense
-
-
-
1
1
3

About SSY Group

View Profile
Address
Rooms 4902-03, 49th Floor
Hong Kong
Hong Kong
Employees -
Website http://www.ssygroup.com.hk
Updated 07/08/2019
SSY Group Ltd. is an investment holding company, which engages in the research, development, and manufacture of pharmaceutical products. It operates through the following segments: Intravenous Infusion Solution and Others; and Medical Materials. The company was founded on September 28, 2004 and is headquartered in Hong Kong.